AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04436159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Addition of 180 posterior fundoplication after crural closure
Description: The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively.
Study NCT04188340 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Su-Man formula massage oil
Description: bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
Study NCT02620722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Tourniquet Instrument
Description: Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
Study NCT02620722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld Doppler ultrasound
Description: Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
Study NCT03980431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FBY PET Examination
Description: A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
Study NCT02000180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Group
Study NCT03774758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Health ct-DNA LUNAR assay
Description: Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
Study NCT04136366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-2191 (intravitreal methotrexate 0.8%)
Description: ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
Study NCT04136366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical care procedure
Description: Standard surgical care performed upon completion of pars plana vitrectomy
Study NCT01444131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline, Nicotine Patch
Description: active nicotine patches added to varenicline.
Study NCT01444131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline and Placebo Patch
Description: placebo nicotine patches added to varenicline.
Study NCT00265629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF catheter ablation
Description: RF ablation using mesh device
Study NCT04597229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Instant multigrain supplement
Description: A twice daily instant multigrain supplementation for 12 weeks
Study NCT02812173 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic tube ex 2 day
Description: balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
Study NCT02812173 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic tube ex 5 day
Description: balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
Study NCT02812173 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral catheter ex 5 day
Description: transurethral catheter withdrawal removal on the fifth day after the surgery
Study NCT04280835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychoeducation that Focused on Social Skill Development
Description: Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
Study NCT01126086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: otamixaban XRP0673
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous
Study NCT04188340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Su-Man formula massage oil
Description: bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
Study NCT04544085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: noise management
Description: The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
Study NCT02551861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Study NCT02551861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Study NCT02551861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT00115648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Oral NVP daily dosage
Study NCT00115648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Oral NVP daily dosage
Study NCT00115648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT
Description: Oral AZT daily
Study NCT00115648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT
Description: Oral AZT daily
Study NCT00115648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP and AZT
Description: Oral single dose NVP plus oral daily AZT during the first weeks
Study NCT00115648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP
Description: Oral NVP daily to age 14 weeks
Study NCT00115648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP+AZT
Description: Oral NVP daily plus oral AZT daly to age 14 weeks
Study NCT01967173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent Diskus® 100 mcg
Description: Flovent is an ICS
Study NCT01967173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent Diskus® 250 mcg
Description: Flovent is an ICS
Study NCT01967173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent Diskus® 500 mcg
Description: Flovent is an ICS
Study NCT01967173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair Diskus® 100/50 mcg
Description: Advair is an ICS/LABA combination
Study NCT01967173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair Diskus® 250/50 mcg
Description: Advair is an ICS/LABA combination
Study NCT04015492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Damoctocog-alfa-pegol (BAY94-9027, Jivi)
Description: Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
Study NCT04015492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol (Adynovi)
Description: Single dose, 50 IU/kg Adynovi
Study NCT01330784 — intervention group
Intervention type: DRUG
Intervention: hMG-HP
Study NCT03666624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized care network
Description: The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
Study NCT00578383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
Study NCT00578383 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
Study NCT03166059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaveoVasc® Thrombolysis Protection System
Description: CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
Study NCT03918161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRE exam
Description: Magnetic Resonance Elastography
Study NCT03524742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado-Mediterranean Diet
Description: Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
Study NCT03524742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-Group Diet
Description: A low fat-high complex carbohydrate diet, during 3 months.
Study NCT02718066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000 in combination with nivolumab
Description: Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice.
Study NCT02037360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator App/Training
Description: This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
Study NCT02037360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental App/Training
Description: It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
Study NCT02302209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02302209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT03383887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo before sleep
Study NCT03383887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAW1033D oral capsule
Description: DAW1033D before sleep
Study NCT02458534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mcgrath Mac videolaryngoscope
Description: Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
Study NCT02458534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Description: Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
Study NCT02458534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: macintosh laryngoscope
Description: Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
Study NCT02086708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave sonoelastography
Description: Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
Study NCT04745702 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Meals Rich in Plant Components
Description: Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
Study NCT04745702 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Low Calorie Balanced Meals
Description: Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
Study NCT02509390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
Study NCT02175537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Social Induction Diabetes and Obesity Program
Description: Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
Study NCT02191423 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: administered pre-fMRI assessment
Study NCT02191423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: administered pre-fMRI assessment
Study NCT02191423 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: administered pre-fMRI assessment
Study NCT02191423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: administered pre-fMRI assessment
Study NCT02191423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic psychotherapy
Study NCT03623841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: Participants in experimental group will do dual-task training via exer-game which combined with treadmill
Study NCT01435239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The cuff inflation by the resting volume
Description: 80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
Study NCT01435239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The cuff inflation by the maximum volume
Description: 80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
Study NCT00640666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Behavior Change
Description: Multidisciplinary
Study NCT03327155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)
Description: One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
Study NCT03604744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.1 mg per os, single dose
Study NCT03604744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: LSD 0.2 mg per os, single dose
Study NCT03604744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.2 mg per os, single dose
Study NCT02197689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Medication Management Platform for SMS Reminder
Description: The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
Study NCT00094809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Study NCT00094809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Study NCT03172208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 1 iv (single-dose)
Description: Single intravenous (iv) administration of Caplacizumab Dose 1
Study NCT03172208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 iv (single-dose)
Description: Single intravenous (iv) administration of Caplacizumab Dose 2
Study NCT03172208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 sc (single-dose)
Description: Single subcutaneous (sc) administration of Caplacizumab Dose 2
Study NCT02802059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EcN-Suspension
Description: Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).
Study NCT02802059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).
Study NCT02772354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
Study NCT02772354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg
Study NCT02772354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Verapamil 20-240 mg
Study NCT02772354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVI-STAR® RMT ThermoCool
Study NCT03196505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 266 MG Per 20 ML Injection
Description: Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Study NCT03172208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab Dose 2 sc (multiple-dose)
Description: Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
Study NCT03172208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo iv (single-dose)
Description: Single intravenous (iv) administration of Placebo
Study NCT03172208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo iv (single-dose)
Description: Single intravenous (iv) administration of Placebo
Study NCT03172208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sc (single-dose)
Description: Single subcutaneous (sc) administration of Placebo